Clinical significance of vascular endothelial growth factor - a expression in Ewing's sarcoma
Clinical significance of vascular endothelial growth factor - a expression in Ewing's sarcoma
复制标题
DOI：
10.1016/j.ejca.2006.01.063
复制
发表时间：
2006-08-01
影响因子：
8.4
通讯作者：
Mesters, Rolf M.
中科院分区：
文献类型：
--
作者：
Kreuter, Michael;Paulussen, Michael;Mesters, Rolf M.
我们研究的目的是进一步了解血管生成在尤文氏肉瘤中的作用。为此，通过定量免疫组织化学方法对 40 名接受标准化新辅助方案治疗的尤文氏肉瘤患者的治疗前活检组织中血管内皮生长因子-A (VEGF-A)、其受体 VEGFR-1 和 -2 的表达以及微血管密度 (MVD) 进行了评估。 VEGF-A 的中位表达水平为 1.5 个任意单位 (AU)，VEGFR-2 的中位表达水平为 8.2 AU，中位 MVD 为 96/0.26 mm(2)。 VEGFR-1 仅在 12.5% 的样本中表达。 VEGF-A 高表达的患者的十年无复发率和总生存率显着较高（分别为 60% 与 29%，p = 0.0216 和 65% 与 25%，p = 0.013）。多变量 Cox 回归分析显示 VEGF-A 表达是生存的独立预后因素。总之，这些数据表明血管生成介质 VEGF 在尤文氏肉瘤中起着重要的预后作用。
The aim of our study was to gain further insight into the role of angiogenesis in Ewing's sarcoma. To this end, expression of Vascular Endothelial Growth Factor-A (VEGF-A), its receptors VEGFR-1 and -2 and microvessel density (MVD) were evaluated by quantitative immunohistochemistry in pretherapeutic biopsies of 40 patients with Ewing's sarcoma treated within standardised neoadjuvant protocols. Median expression levels were 1.5 arbitrary units (AU) for VEGF-A, 8.2 AU for VEGFR-2 and median MVD was 96/0.26 mm(2). VEGFR-1 was expressed in 12.5% of the samples, only. Ten-year relapse free and overall survival rates were significantly higher for patients with high VEGF-A expression (60% versus 29%, p = 0.0216 and 65% versus 25%, p = 0.013, respectively). Multivariate Cox regression analysis revealed that VEGF-A expression was an independent prognostic factor for survival. In conclusion, these data suggest that the angiogenic mediator VEGF plays an important prognostic role in Ewing's sarcoma.